All studies were conducted in accordance with the GSK Policy
on the Care, Welfare and Treatment of Laboratory Animals and
were reviewed the Institutional Animal Care and Use Committee
either at GSK or by the ethical review process at the institution
where the work was performed.
14. Takeshita, E.; Komaki, H.; Shimizu-Motohashi, Y.;
Ishiyama, A.; Sasaki, M.; Takeda, S. A phase I study of
TAS-205 in patients with Duchenne muscular dystrophy.
Ann. Clin. Trans. Neurol. 2018, 5, 1338-1349.
15. FP assay was purchased as a H-PGDS FP-Based Inhibitor
Screening Assay Kit – Green from Cayman Chemical
References
1. Vane, J. R. Inhibition of prostaglandin synthesis as a
mechanism of action for aspirin-like drugs. Nat. New Biol.
1971, 231, 232–235.
16. Sou, T.; Bergström, C. A. S. Automated assays for
thermodynamic (equilibrium) solubility determination.
Drug Disc. Today: Technologies, 2018, 27, 11-19.
2. Laine, L. Approaches to nonsteroidal anti-inflammatory
drug use in the high-risk patient. Gastroenterology 2001,
120, 594-606.
17. Veber, D.F.; Johnson, S.R.; Chen, H-Y.; Smith, B. R.;
Ward, K. W.; Kopple, D. Molecular properties that
influence the oral bioavailability of drug candidates. J.
Med. Chem. 2002, 45, 2615-2623.
3. Nussmeier, N. A.; Whelton, A. A.; Brown, M. T.;
Langford, R. M.; Hoeft, A.; Parlow, J. L.; Boyce, S. W.;
Verburg, K. M. Complications of the COX-2 inhibitors
parecoxib and valdecoxib after cardiac surgery. N. Engl. J.
Med. 2005, 352, 1081-1091.
18. Kansy, M.; Senner, F.; Gubernator, K. Physicochemical
high throughput screening: parallel artificial membrane
permeation assay in the description of passive absorption
processes. J. Med. Chem. 1998, 41, 1007–1010.
4. Bresalier, R. S.; Sandler, R. S.; Quan, H.; Bolognese, J. A.;
Oxenius, B.; Horgan, K.; Lines, C.; Riddell, R.; Morton,
D.; Lanas, A.; Konstam, M. A.; Baron, J. A. Cardiovascular
events associated with rofecoxib in a colorectal adenoma
chemoprevention trial. N. Engl. J. Med. 2005, 352, 1092-
1102.
19. Hopkins, A.L.; Groom, C.R.; Alex, A. Ligand efficiency: a
useful metric for lead election. Drug Disc. Today. 2004, 9,
430-431.
5. Smith, W. L.; Urade, Y.; Jakobsson P.-J. Enzymes of the
cyclooxygenase pathways of prostanoid biosynthesis.
Chem. Rev. 2011, 111, 5821-5865.
20. Saxty, G.; Norton, D.; Affleck, K.; Clapham, D.; Cleasby,
A.; Coyle, J.; Day, P.; Frederickson, M.; Hancock, A.;
Hobbs, H.; Hutchinson, J.; Le, J.; Leveridge, M.;
McMenamin, R.; Mortenson, P.; Page, L.; Richardson, C.;
Russell, L.; Sherriff, E.; Teague, S.; Uddin, S.; Hodgson, S.
Identification of orally bioavailable small-molecule
inhibitors of hematopoietic prostaglandin D2 synthase
using X-ray fragment based drug discovery.
MedChemComm. 2014, 5, 134-141.
6. Watanabe, K. Recent reports about enzymes related to the
synthesis of prostaglandin (PG) F2 (PGF2α and 9α, 11β-
PGF2). J. Biochem. 2011, 150, 593-596.
7. Kupczyk,
M.;
Kuna,
P.
Targeting
the
PGD2/CRTH2/DP1signaling pathway in asthma and
allergic disease: Current status and future perspectives.
Drugs 2017, 77, 1281–1294.
21. Deaton, D. N.; Do, Y.; Holt, J.; Jeune, M. R.; Kramer, H.
F.; Larkin, A. L.; Orband-Miller, L. A.; Peckham, G. E.;
Poole, C.; Price, D. J.; Schaller, L. T.; Shen, Y.;
Shewchuck, L. M.; Stewart, E. L.; Stuart, J. D.; Thomson,
S. A.; Ward, P.; Wilson, J. W.; Xu, T.; Guss, J. H.; Musetti,
C.; Rendina, A. R.; Affleck, K.; Anders, D.; Hancock, A.
P.; Hobbs, H.; Hodgson, S. T.; Hutchinson, J.; Leveridge,
M. V.; Nicholls, H.; Smith, I. E. D.; Somers, D. O.;
Sneddon, H. F.; Uddin, S.; Cleasby, A.; Mortenson, P. N.;
Richardson, C.; Saxty, G. The Discovery of quinoline-3-
carboxamides as hematopoietic prostaglandin D synthase
(H-PGDS) inhibitors. Bioorg. Med. Chem. 2019, 27, 1456-
1478.
8. Thurairatnam, S. Hematopoietic prostaglandin D synthase
inhibitors. Prog. Med. Chem. 2012, 51, 97-133.
9. Hesterkamp, T.; Barker, J.; Davenport, A.; Whittaker, M.
Fragment based drug discovery using fluorescence
correlation spectroscopy techniques: Challenges and
solutions. Curr. Top. Med. Chem. 2007, 7, 1582-1591.
10. Hohwy, M.; Spadola, L.; Lundquist, B.; Hawtin, P.;
Dahmén, J.; Groth-Clausen, I.; Nilsson, E.; Persdotter, S.;
von Wachenfeldt, K.; Folmer, R.H.A.; Edman; K. Novel
prostaglandin D synthase inhibitors generated by fragment-
based drug design. J. Med. Chem. 2008, 51, 2178-2186.
22. Dhar, T. G. M.; Wrobleski, S. T. Preparation of
heterobicyclic compounds as p38 kinase inhibitors.
US 20080275052 A1, 2008
11. Weiberth, F.J.; Yu, Y.; Subotkowski, W.; Pemberton, C.
Demonstration on pilot-plant scale of the utility of 1,5,7-
triazabicyclo[4.4.0]dec-5-ene (TBD) as a catalyst in the
efficient amidation of an unactivated methyl ester. Org.
Proc. Res. Devel. 2012, 16, 1967-1969.
23. Connolly, P. J.; Bian, H.; Li, X.; Liu, L.; Macielag, M. J.;
McDonnell, M. E. Azetidinylpiperidine derivatives as
monoacylglycerol lipase inhibitors and their preparation
and use for the treatment of inflammatory pain.
WO1205471, 2012
12. Carron, C.P.; Trujillo, J.I.; Olson, K. L. Discovery of an
oral potent selective inhibitor of hematopoietic
prostaglandin D synthase (HPGDS) ACS. Med. Chem. Lett.
2010, 1, 59-63.
24. Lipinski, C. A. Drug-like properties and the causes of poor
solubility and poor permeability. J. Pharmacology Toxicol.
Methods. 2000, 44, 235–249.
13. Komaki, H.; Maegaki, Y.; Matsumura, T. Early phase 2
trial of TAS-205 in patients with Duchenne muscular
dystrophy. Ann. Clin. Transl. Neurol. 2020, 7, 181-190.